This is a study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HRS-6209 combined with other treatment regimens in breast cancer patients, and preliminarily observe its anti-tumor efficacy.
Women aged 18-75 years.
ECOG performance status 0-1.
Menopausal status.
Evidence of radiographic disease progression during or after the last systemic anti-tumor therapy prior to the first study drug administration.
Symptomatic visceral metastasis and other conditions, and the researcher judged that endocrine therapy was not suitable for use.
History of clinically serious cardiovascular disease.
The ECG examination was abnormal.
Patients with clinically significant endometrial abnormalities, including but not limited to endometrial hyperplasia and dysfunctional uterine bleeding.